In previous studies, the administration of FLT3LG involved the injection of synthetic adenoviruses, vaccines, recombinant proteins, or similar agents into the bodies or tumors of the subjects under investigation to promote overall immune cell proliferation or immune cell infiltration in the tumor microenvironment, thereby indirectly inducing antitumor effects through the modulation of immune cells and immune status [32, 33, 42, 43]. The gene discussed is FLT3LG; the disease is neoplasm.